A Phase Ib Feasibility Study of Personalized Kinase Inhibitor Therapy Combined with Induction Chemotherapy in Acute Myeloid Leukemia in Patients who Exhibit in vitro Kinase Inhibitor Sensitivity
The purpose of this research study is to test the safety of adding a targeted study drug after receiving the standard 7+3 chemotherapy treatment for AML. The pathways responsible for activating the growth of leukemia cells can be unique to each patient and can change during the course of the disease. The lab test developed by the investigators at OHSU will help screen your blood or bone marrow to find out if your cancer may be sensitive to a specific study drug. This is called “targeted therapy”. The reason for doing this research study is to see if the new investigational screening lab test can help provide individualized treatment for patients with leukemia. This study will allow the researchers to learn more about how AML responds to treatment.
Newly diagnosed acute myeloid leukemia (AML).
Newly diagnosed acute myeloid leukemia (AML) and physician recommendation based on study inclusion and exclusion criteria.
21 - No Upper Age Limit
Healthy Volunteers Needed
Duration of Participation
Treatment period of 1 month. Follow-up for 1 year.
Tara Macey, PhD
Stephen Spurgeon, MD